gyki 53655 has been researched along with Seizures in 2 studies
*Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder. [MeSH]
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baraldi, M; De Micheli, C; De Sarro, A; De Sarro, G; Grasso, S; Micale, N; Puia, G; Zappalà, M | 1 |
Gacsályi, I; Gigler, G; Gyertyán, I; Lévay, G; Szabados, T | 1 |
2 other study(ies) available for gyki 53655 and Seizures
Article | Year |
---|---|
Synthesis and anticonvulsant activity of novel and potent 2,3-benzodiazepine AMPA/kainate receptor antagonists.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Cells, Cultured; Convulsants; Drug Evaluation, Preclinical; Electroshock; Excitatory Amino Acid Antagonists; Kainic Acid; Male; Mice; Mice, Inbred DBA; Motor Activity; Neurons; Patch-Clamp Techniques; Pentylenetetrazole; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Kainic Acid; Seizures | 1999 |
Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655.
Topics: Acoustic Stimulation; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Brain Ischemia; Dose-Response Relationship, Drug; Electroshock; Magnesium Chloride; Male; Mice; Mice, Inbred Strains; Neuroprotective Agents; Seizures; Survival Analysis; Time Factors | 2001 |